The data displayed by Mercury’s I-O star Keytruda on the ASCO 2018 is amazing, and almost everyone believes that Keytruda has no doubt seized the throne of lung immunotherapy. However, competitors do not seem to agree with this. In their view, the difference between their drug and Keytruda is very… Continue Reading What is the difference between the PD-1/PD-L1 drugs in Merck, BMS, and Roche?
MSD announced on May 23 that a key Phase III study of Keytruda (pembrolizumab) combined with chemotherapy (carboplatin + paclitaxel or naproxen + paclitaxel) for the first-line treatment of metastatic squamous NSCLC achieved overall survival (OS) and progression-free survival ( The two primary endpoints of PFS). The results of an… Continue Reading Keytruda first-line treatment of squamous NSCLC achieves double primary endpoint
Viagra From the failure of cardiovascular medications to the great success of ED indications In the 1980s, scientists at Pfizer’s European Research Center have been looking for drugs to treat cardiovascular diseases such as angina. The commonly used nitrates at that time were prone to tolerance. At that time, basic… Continue Reading How did innovative drugs fail from Viagra to PD-1?
IDO Inhibitor Stops Recruiting Patients in Multiple Clinical Trials On May 2, Incyte announced that multiple late-stage clinical trials of epacadostat with MSD, Bristol-Myers Squibb, and Aslicon PD-1/PD-L1 drugs will stop the recruitment of patients. At the same time, Bristol-Myers Squibb also stopped several clinical trials with the PD-1 combination… Continue Reading A week of news